Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
43.8 EUR | -1.57% | +0.11% | -2.85% |
Jul. 01 | STRATEC BIOMEDICAL SYSTEMS AG : Gets a Neutral rating from Deutsche Bank | ZD |
Jun. 11 | STRATEC BIOMEDICAL SYSTEMS AG : Warburg Research reiterates its Neutral rating | ZD |
Valuation
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Capitalization 1 | 733.5 | 1,485 | 1,669 | 983.7 | 553.7 | 540.9 | - | - |
Enterprise Value (EV) 1 | 810.8 | 1,567 | 1,705 | 983.7 | 520.2 | 657 | 626.8 | 616.4 |
P/E ratio | 45.5 x | 59.3 x | 42 x | 33.8 x | 42.6 x | 33.1 x | 23.4 x | 20.2 x |
Yield | 1.38% | 0.73% | 0.69% | - | 1.21% | 1.95% | 2.04% | 2.22% |
Capitalization / Revenue | 3.31 x | 5.94 x | 5.81 x | 3.58 x | 2.11 x | 2.03 x | 1.87 x | 1.74 x |
EV / Revenue | 3.66 x | 6.27 x | 5.94 x | 3.58 x | 1.99 x | 2.46 x | 2.17 x | 1.98 x |
EV / EBITDA | 19.8 x | 30.2 x | 25.6 x | 16.8 x | 12.5 x | 13.4 x | 10.8 x | 9.75 x |
EV / FCF | 159 x | 90.7 x | 39.4 x | - | 46.9 x | 17.3 x | 16 x | 19.7 x |
FCF Yield | 0.63% | 1.1% | 2.54% | - | 2.13% | 5.78% | 6.26% | 5.08% |
Price to Book | 4.61 x | 8.61 x | 8.12 x | - | 2.37 x | 2.25 x | 2.13 x | 2 x |
Nbr of stocks (in thousands) | 12,025 | 12,090 | 12,111 | 12,130 | 12,156 | 12,156 | - | - |
Reference price 2 | 61.00 | 122.8 | 137.8 | 81.10 | 45.55 | 44.50 | 44.50 | 44.50 |
Announcement Date | 4/2/20 | 3/31/21 | 3/30/22 | 3/28/23 | 3/28/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net sales 1 | 221.6 | 250.1 | 287.3 | 274.6 | 261.9 | 267.1 | 288.9 | 311 |
EBITDA 1 | 40.85 | 51.98 | 66.61 | 58.58 | 41.58 | 49.21 | 57.83 | 63.24 |
EBIT 1 | 31.15 | 41.71 | 54.27 | 45.05 | 27.07 | 28.48 | 35.94 | 40.2 |
Operating Margin | 14.05% | 16.68% | 18.89% | 16.41% | 10.34% | 10.66% | 12.44% | 12.93% |
Earnings before Tax (EBT) 1 | 18.32 | 33.02 | 46.83 | 39.09 | 18.23 | 21.45 | 29.95 | 35.28 |
Net income 1 | 14.44 | 25.18 | 39.96 | 29.22 | 13.07 | 16.44 | 23.04 | 26.78 |
Net margin | 6.52% | 10.07% | 13.91% | 10.64% | 4.99% | 6.16% | 7.97% | 8.61% |
EPS 2 | 1.340 | 2.070 | 3.280 | 2.400 | 1.070 | 1.343 | 1.904 | 2.208 |
Free Cash Flow 1 | 5.115 | 17.28 | 43.24 | - | 11.08 | 37.97 | 39.22 | 31.33 |
FCF margin | 2.31% | 6.91% | 15.05% | - | 4.23% | 14.22% | 13.58% | 10.08% |
FCF Conversion (EBITDA) | 12.52% | 33.24% | 64.92% | - | 26.66% | 77.15% | 67.82% | 49.54% |
FCF Conversion (Net income) | 35.42% | 68.63% | 108.22% | - | 84.82% | 230.91% | 170.23% | 116.99% |
Dividend per Share 2 | 0.8400 | 0.9000 | 0.9520 | - | 0.5500 | 0.8697 | 0.9059 | 0.9880 |
Announcement Date | 4/2/20 | 3/31/21 | 3/30/22 | 3/28/23 | 3/28/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2019 S2 | 2022 Q1 | 2022 Q2 | 2022 S1 | 2022 Q3 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 |
---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | 111.3 | 75.39 | 61.81 | 137.2 | 70.46 | 60.48 | 64.53 | 62.67 | 74.23 | 50.87 |
EBITDA | 23.51 | - | - | - | - | - | - | - | - | - |
EBIT 1 | 18.43 | 15.04 | 6.141 | 21.18 | - | 3.816 | - | - | 10.85 | 3.145 |
Operating Margin | 16.56% | 19.95% | 9.94% | 15.44% | - | 6.31% | - | - | 14.62% | 6.18% |
Earnings before Tax (EBT) | - | - | - | - | - | - | - | - | - | - |
Net income | - | - | - | - | - | - | - | - | - | - |
Net margin | - | - | - | - | - | - | - | - | - | - |
EPS | - | - | - | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 4/2/20 | 5/5/22 | 8/10/22 | 8/10/22 | 11/3/22 | 4/28/23 | 9/5/23 | 10/28/23 | 3/28/24 | 4/26/24 |
Balance Sheet Analysis
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net Debt 1 | 77.3 | 82.7 | 36.6 | - | - | 116 | 85.8 | 75.5 |
Net Cash position 1 | - | - | - | - | 33.5 | - | - | - |
Leverage (Debt/EBITDA) | 1.891 x | 1.591 x | 0.5491 x | - | - | 2.358 x | 1.484 x | 1.194 x |
Free Cash Flow 1 | 5.12 | 17.3 | 43.2 | - | 11.1 | 38 | 39.2 | 31.3 |
ROE (net income / shareholders' equity) | 9.28% | 15.2% | 21.1% | - | 7.29% | 8.09% | 9.87% | 10.9% |
ROA (Net income/ Total Assets) | 5.03% | 7.98% | 11.4% | - | 3.87% | 3.01% | 4.62% | 5.66% |
Assets 1 | 287.3 | 315.7 | 350.2 | - | 337.9 | 545.8 | 498.7 | 473.3 |
Book Value Per Share 2 | 13.20 | 14.30 | 17.00 | - | 19.20 | 19.80 | 20.90 | 22.20 |
Cash Flow per Share 2 | 1.760 | 2.620 | 5.210 | - | 1.600 | 3.030 | 3.100 | 3.450 |
Capex 1 | 16.1 | 14.6 | 20.2 | - | 17.4 | 22.3 | 21.4 | 22.3 |
Capex / Sales | 7.29% | 5.83% | 7.04% | - | 6.65% | 8.36% | 7.4% | 7.18% |
Announcement Date | 4/2/20 | 3/31/21 | 3/30/22 | 3/28/23 | 3/28/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-2.85% | 590M | |
+3.66% | 208B | |
+7.50% | 182B | |
+30.03% | 155B | |
+34.80% | 115B | |
+2.43% | 66.52B | |
+16.41% | 53.93B | |
-4.51% | 46.26B | |
-4.50% | 38.22B | |
+4.81% | 36.6B |
- Stock Market
- Equities
- SBS Stock
- Financials Stratec SE